G6PD: glucose-6-phosphate dehydrogenase.
* Topical tacrolimus is our preferred initial treatment based on a low likelihood of cosmetically significant adverse effects.
¶ We generally reserve topical corticosteroids for patients who cannot tolerate or decline intralesional corticosteroid therapy. Cutaneous atrophy is a risk of corticosteroid treatment. Risks of cryotherapy include dyspigmentation and scarring.
Administration considerations are as follows:Δ Screening for G6PD deficiency should be performed prior to starting dapsone. Patients with G6PD deficiency have an increased risk for hematologic complications from dapsone. Refer to UpToDate content on granuloma faciale for details on dapsone and other treatments.
Do you want to add Medilib to your home screen?